RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eurofins-Cerep Stock

Eurofins-Cerep P/E 2024

Eurofins-Cerep P/E

8.83

Ticker

ALECR.PA

ISIN

FR0013256518

WKN

A2DT0B

As of Sep 26, 2024, Eurofins-Cerep's P/E ratio was 8.83, a 27.79% change from the 6.91 P/E ratio recorded in the previous year.

The Eurofins-Cerep P/E history

Eurofins-Cerep Aktienanalyse

What does Eurofins-Cerep do?

Eurofins-Cerep SA is a globally renowned biotechnology company that was founded in 1993. With its headquarters in Paris, France, the company operates over 47 locations worldwide and employs over 45,000 employees. The company specializes in the development and commercialization of innovative biological technologies for use in the pharmaceutical industry. Eurofins-Cerep focuses on the discovery of new drugs for the treatment of diseases such as cancer, Alzheimer's, Parkinson's, and diabetes. The business model of Eurofins-Cerep is based on three pillars: services, product sales, and research and development offerings. Under the "services" division, the company offers extensive pharmacological and biological testing and screening procedures for drug compounds to its customers. Eurofins-Cerep has a wide range of assays and tests that allow customers to assess and optimize the efficacy and safety of their drug compounds. The "product sales" division includes the manufacturing and distribution of over 1,000 different biological reagents, antibodies, and other products for biomedical research. The company specializes in producing reagents used in drug development, such as G-protein coupled receptors (GPCRs). The third pillar of Eurofins-Cerep's business model consists of research and development services for customers and partners. The company supports customers in identifying new drug compounds and developing drug candidates up to market approval. The company has various divisions, including the Cerep division, which specializes in the evaluation of potential drug candidates and associated toxicology. The Eurofins Pharma Discovery Services division offers advanced drug optimization and screening services by providing customized approaches to drug development. The Eurofins BioPharma Services division is a leading provider of complete solutions in the pharmaceutical development and GxP laboratories. The company is also active in other areas such as the environment and the food industry. Eurofins-Cerep has made several acquisitions in the past, including the acquisition of XDS Laboratories, a leading provider of clinical laboratory services, and EAG Laboratories, a highly specialized analysis and testing service unit. Overall, Eurofins-Cerep SA has achieved numerous milestones in the past 28 years and has become one of the world's leading providers of biological screening and analysis technologies. The company remains committed to offering its customers innovative biological technologies and maintaining its reputation as a reliable partner in the pharmaceutical industry. Eurofins-Cerep ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Eurofins-Cerep's P/E Ratio

The Price to Earnings (P/E) Ratio of Eurofins-Cerep is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Eurofins-Cerep's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Eurofins-Cerep is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Eurofins-Cerep’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Eurofins-Cerep stock

What is the price-to-earnings ratio of Eurofins-Cerep?

The price-earnings ratio of Eurofins-Cerep is currently 8.83.

How has the price-earnings ratio of Eurofins-Cerep changed compared to last year?

The price-to-earnings ratio of Eurofins-Cerep has increased by 27.79% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Eurofins-Cerep high compared to other companies?

Yes, the price-to-earnings ratio of Eurofins-Cerep is high compared to other companies.

How does an increase in the price-earnings ratio of Eurofins-Cerep affect the company?

An increase in the price-earnings ratio of Eurofins-Cerep would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Eurofins-Cerep affect the company?

A decrease in the price-earnings ratio of Eurofins-Cerep would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Eurofins-Cerep?

Some factors that influence the price-earnings ratio of Eurofins-Cerep are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Eurofins-Cerep pay?

Over the past 12 months, Eurofins-Cerep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eurofins-Cerep is expected to pay a dividend of 0 EUR.

What is the dividend yield of Eurofins-Cerep?

The current dividend yield of Eurofins-Cerep is .

When does Eurofins-Cerep pay dividends?

Eurofins-Cerep pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eurofins-Cerep?

Eurofins-Cerep paid dividends every year for the past 0 years.

What is the dividend of Eurofins-Cerep?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eurofins-Cerep located?

Eurofins-Cerep is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eurofins-Cerep kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eurofins-Cerep from 9/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Eurofins-Cerep pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Eurofins-Cerep in the year 2023?

In the year 2023, Eurofins-Cerep distributed 0 EUR as dividends.

In which currency does Eurofins-Cerep pay out the dividend?

The dividends of Eurofins-Cerep are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Eurofins-Cerep

Our stock analysis for Eurofins-Cerep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eurofins-Cerep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.